Joe Ma Research Interests: Drug Metabolism/PK and Pain Past: Examined and validated methods to evaluate drug-drug interaction/phenotyping studies (e.g., single point or limited sampling, metabolic ratios, bias/precision estimates, etc.) Present: Continuing drug metabolism/PK but focused on pain management and opioid metabolism

Core Expertise Phenotyping drug metabolizing enzyme activity Use of probe drugs as biomarkers Drug-drug interaction study design (‘phenotyping cocktails’) Pain Management Current clinical practice in pain and palliative care Opioid metabolism and pharmacokinetics

Proposed Collaborations with SSPPS Faculty Future (1-2 years) Question clinical practice approaches in pain management Evaluate ‘weighting’ of current drug misuse/abuse screening tools Determine suitability of current, in vivo, CYP2B6 and P-gp drug probes Methadone (CYP2B6), fexofenadine (P-gp) Horizon (3-4 years) Discovery orientated data mining; increase use of publically available data Surveillance, Epidemiology, and End Results Program (SEER by NCI) includes palliative care-related data and medication use data ( , ~8 million patient cases) FDA’s Adverse Event Report System (AERS; ~2.7 million Adverse events)